Skip to content
2000
Volume 14, Issue 3
  • ISSN: 1573-4099
  • E-ISSN: 1875-6697

Abstract

Introduction: Morbidity and mortality due to tuberculosis are rising steadily. Despite having efficient drugs and treatment protocols, microbial drug resistance often leads to treatment failure. Efforts to bring novel drugs to combat this menace are hampered by several issues including problems in gaining industry support, motivation and ethical issues clinical trials. Bedaquiline and Delaminid are the only novel drugs approved in the last three decades for treating TB. A few more molecules and drug combinations are still in clinical trials. One such drug is the BM212, a potent anti-TB agent which acts by a novel mechanism of action. Methods: In the present study, we used virtual screening method with a combination of molecular hybridization technique to design N-benzylated Indole Mannich bases as potent anti-TB agent based on BM212 pharmacophore. The library of designed molecules was prepared and screened using BM212 model. The top 5 ‘hit’ molecules were selected (with good TC score >1.15), synthesized and screened for anti TB activity by MABA assay method. Results and Conclusion: All the compounds showed excellent anti TB activity, of which 4 compounds have shown MIC ≤12.5 μg/mL. Our protocol could help in the designing of newer anti-TB agents with better bioactivity profile.

Loading

Article metrics loading...

/content/journals/cad/10.2174/1573409914666180423093049
2018-09-01
2025-05-10
Loading full text...

Full text loading...

/content/journals/cad/10.2174/1573409914666180423093049
Loading

  • Article Type:
    Research Article
Keyword(s): MABA; mannich bases; Molecular hybridization; morbidity; mortality; virtual screening
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test